Straumann Introduces New Oral Bone Regeneration Gel

Straumann, based in Basel, Switzerland, recently announced launch of its MembraGelproduct, a membrane for use in guided oral bone regeneration procedures.

MembraGel is a polyethylene glycol membrane that is applied as a liquid and sets in situ. Because the technology requires different handling than conventional membranes, the company is combining the launch with an education program that includes hands-on product training. In addition, the product only will be available to dental professionals who have participated in the program.

“Straumann MembraGel offers a unique combination of benefits and we are convinced that it will set new standards in surgical implantology,” said Sandro Matter, executive vice president of products at Straumann.

“Throughout development, we have worked closely with leading independent experts and have decided to launch the product in combination with an education program because we want customers to achieve optimum results from the outset. This is the appropriate way to introduce new technologies and shows that we take our responsibilities as an innovator seriously.”

According to the company’s market research, at least one in four implant procedures requires bone augmentation either prior to, or concurrent with, implant placement. Guided bone regeneration involves the use of a barrier membrane to help stabilize the bone graft and prevent unwanted growth of soft-tissue into the defect. The company estimates the global market for these products is to be worth more than $200 million.

Commonly used conventional membranes are supplied as prefabricated sheets and have to be cut to fit the defect—often using a template. In some cases, the membrane also needs to be secured by pinning. Furthermore, non-resorbable membranes need to be surgically removed after the healing process has taken place.

MembraGel is applied in liquid form and molds to the defect precisely. Within 20-50 seconds after application, the liquid components solidify, stabilizing the bone graft and providing an effective barrier to tissue infiltration. Preclinical studies have shown that the surgical site is protected over the period required for bone formation with no abnormal soft-tissue reaction. The substance then subsequently biodegrades.

MembraGel initially is being launched initially in key European markets, North America and Australia, where it has received regulatory approvals.